Avantor Directors Buy $1.3M of Stock Near $8 Per Share

NEW YORK, May 24 —

Three Avantor directors made open-market purchases totaling roughly $1.29 million at prices near $8 per share between March and May 2026. The window spans before and after the company's Q1 2026 earnings release. Around the same time, Yacktman Asset Management opened a new $37.2 million position in the stock. Three insiders and one outside value manager bought the same equity in the same quarter, at prices no one forced them to pay.

Three Purchases, One Direction

The buying started with Director Sanjeev K. Mehra, who acquired 125,000 shares at $8.01 on March 10 for $1,001,250. That was before Q1 results. Director Simon Dingemans followed on May 1, buying 25,000 shares at $8.14 for $203,500. Director Gregory T. Lucier closed out the sequence on May 8 with 10,000 shares at $8.32, an $83,200 purchase. Dingemans and Lucier bought after Q1 earnings were public. The results did not stop them.

The sequence answers a simple question: was the pre-earnings buyer lucky, or did the thesis hold after the numbers came out? Two more directors bought after Q1. The price moved a few cents between the three transactions. The direction never changed.

Directors who buy on the open market are not exercising options granted as compensation. They are writing personal checks at a specific price, with full knowledge of where the business stands internally. That does not guarantee they are right. It does mean they had a view and acted on it.

What the Numbers Say

Avantor's Q1 2026 results, disclosed in an 8-K filed April 29, continued a pattern of narrow shortfalls. In the three most recently reported quarters, the company posted EPS of $0.24 against a consensus of $0.25, $0.22 against $0.23, and $0.22 against a prior-period estimate of $0.22. Two misses and one that came in roughly at consensus.

Revenue on a trailing twelve-month basis stands at $6.55 billion. Growth is 0.0%. Avantor supplies critical materials to pharmaceutical manufacturers, biotech labs, and advanced manufacturing facilities — all sectors that have expanded steadily — yet its top line has not moved in a year. Free cash flow came in at $489 million on a trailing basis. Gross margin sits at 32.1%, reasonable for a business with significant distribution exposure. The business generates cash. It is not growing.

A company generating $489 million in free cash flow while trading near $8 per share is either deeply undervalued or carrying problems that justify the discount. The insider buying argues for the former. The flat revenue argues for skepticism.

The Yacktman Factor

Yacktman Asset Management's $37.2 million new position in AVTR is not a board member's vote of confidence — it is outside capital making a cold fundamental call. Yacktman is a value-oriented firm that buys durable businesses at prices below intrinsic worth. A fresh $37 million position in a company with flat revenue and a stock near multi-year lows is not a momentum trade.

Three insiders and one external value manager reached the same conclusion about Avantor in the same quarter. They bought at the same price range. No catalyst was announced. That convergence is worth noting.

The Hire That Fits the Thesis

Avantor appointed Jerry Porreca as EVP for global quality and regulatory oversight, per a regulatory filing and press reports. For a supplier to pharmaceutical manufacturers subject to FDA and EMA scrutiny, quality failures at a customer facility quickly become the supplier's problem. Regulators trace problems upstream. Putting a dedicated EVP on this function is a client retention move, not an expansion play.

The hire does not move revenue today. It fits a pattern of operational discipline from a team betting the current slowdown is cyclical, not permanent.

What Changes the Thesis

The bull case for Avantor at $8 is mean reversion. Life sciences supply markets do not stay flat indefinitely. Biopharma customers that deferred capital spending eventually place orders. A business generating $489 million in free cash flow with a 32.1% gross margin has real value. The directors buying near $8 are betting the stock price does not reflect it.

The bear case is simpler: flat revenue stays flat until something changes, and nothing in the available evidence names what restarts growth. Narrow EPS misses do not become beats on their own. Three directors spending $1.3 million is a signal, not a schedule.

The next checkpoint is the next quarterly earnings report. A clean beat with raised guidance would validate the insider buying. Another narrow miss, or a fourth straight quarter of flat revenue, would force harder questions about whether anything actually changes. Until then, the read is straightforward: informed capital is buying at these levels, but the event that proves the buyers right has not happened yet.

Run the free Avantor, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

Why are Avantor directors buying stock now?

Three Avantor directors made open-market purchases totaling $1.29 million between March and May 2026 at prices between $8.01 and $8.32 per share, per Form 4 filings. The purchases come from three independent decision-makers and include buys made after Q1 2026 earnings were already public. Zero open-market sales were reported in the same 90-day window.

What were Avantor's Q1 2026 earnings results?

Avantor filed an 8-K on April 29, 2026 disclosing Q1 2026 results. In the three most recently reported quarters, the company posted EPS of $0.24, $0.22, and $0.22 against consensus estimates of $0.247, $0.225, and $0.217 respectively, per Yahoo Finance data. Each quarter fell short of estimates, as biopharma customers pulled back on purchasing.

Is Avantor free cash flow positive?

Yes. Avantor generated $489 million in free cash flow on a trailing twelve-month basis, even as reported revenue has been flat at $6.55 billion. A 32.1% gross margin reflects the pricing power of Avantor's proprietary materials and reagent formulations, which carry real customer switching costs.

What is Yacktman's position in Avantor stock?

Yacktman Asset Management LP opened a new $37.2 million position in AVTR. Yacktman is a value-oriented, patient manager. The position is an independent data point: an outside firm buying at the same price levels — near $8 per share — where three company directors were also buying.

What is Avantor's revenue growth rate?

Avantor reported trailing twelve-month revenue of $6.55 billion with year-over-year growth of 0.0%. The life science tools sector ran down excess pandemic-era inventory over the past two years, and Avantor's top line has not recovered yet. Flat revenue is the central risk. Watch the quarterly disclosures for any sign of acceleration.